Premium
Letter: switching from one to another anti‐tumour necrosis factor alpha agent, and the risks of an overlap of exposure – authors' reply
Author(s) -
Gisbert J. P.,
Chaparro M.
Publication year - 2016
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13579
Subject(s) - medicine , infliximab , adalimumab , adverse effect , tumor necrosis factor alpha , perforation , incidence (geometry) , gastroenterology , punching , materials science , physics , optics , metallurgy